Venrock Healthcare Capital Partners III, L.P.
SEC insider (Form 3/4/5 filer). CIK 0001738048. 10% Owner at Lycia Therapeutics, Inc. (LYCA) and 2 other issuers. 19 reported Form 4/5 transactions since Sep 2024; latest on Mar 26, 2026. Located in NEW YORK, NY.
Companies Venrock Healthcare Capital Partners III, L.P. has filed insider reports for
- Lycia Therapeutics, Inc. (LYCA): 10% Owner
- KalVista Pharmaceuticals, Inc. (KALV): 10% Owner
- Oruka Therapeutics, Inc. (ORKA): 10% Owner
Venrock Healthcare Capital Partners III, L.P.
CIK: 0001738048
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (19 total)
- Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
SaleIndirect3.2K shares at avg. $19.12$61K - Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
SaleIndirect15.4K shares at avg. $18.82$290K - Mar 26, 2026KALV
KalVista Pharmaceuticals, Inc.
SaleIndirect21.4K shares at avg. $17.76$380K - Mar 25, 2026KALV
KalVista Pharmaceuticals, Inc.
SaleIndirect174.5K shares at avg. $16.95$3.0M - Mar 25, 2026KALV
KalVista Pharmaceuticals, Inc.
SaleIndirect160 shares at avg. $17.53$3K - Apr 9, 2025KALV
KalVista Pharmaceuticals, Inc.
PurchaseIndirect25K shares at avg. $9.42$236K - Feb 14, 2025ORKA
Oruka Therapeutics, Inc.
PurchaseIndirect88.8K shares at avg. $11.44$1.0M - Feb 13, 2025ORKA
Oruka Therapeutics, Inc.
PurchaseIndirect15K shares at avg. $11.63$174K - Feb 13, 2025KALV
KalVista Pharmaceuticals, Inc.
PurchaseIndirect61.7K shares at avg. $9.33$576K - Feb 12, 2025ORKA
Oruka Therapeutics, Inc.
PurchaseIndirect9K shares at avg. $11.86$106K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 26, 2026 |  KALV KalVista Pharmaceuticals, Inc. | Sale | 3,183 | $19.12 | $60,859 | Indirect |
| Mar 26, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale | 15,417 | $18.82 | $290,148 | Indirect |
| Mar 26, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale | 21,386 | $17.76 | $379,815 | Indirect |
| Mar 25, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale | 174,485 | $16.95 | $2,957,521 | Indirect |
| Mar 25, 2026 | KALV KalVista Pharmaceuticals, Inc. | Sale | 160 | $17.53 | $2,805 | Indirect |
| Apr 9, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase | 25,000 | $9.42 | $235,500 | Indirect |
| Feb 14, 2025 |  ORKA Oruka Therapeutics, Inc. | Purchase | 88,794 | $11.44 | $1,015,803 | Indirect |
| Feb 13, 2025 | ORKA Oruka Therapeutics, Inc. | Purchase | 14,950 | $11.63 | $173,869 | Indirect |
| Feb 13, 2025 | KALV KalVista Pharmaceuticals, Inc. | Purchase | 61,700 | $9.33 | $575,661 | Indirect |
| Feb 12, 2025 | ORKA Oruka Therapeutics, Inc. | Purchase | 8,971 | $11.86 | $106,396 | Indirect |
1-10 of 19 transactions